MDGL
Price
$216.05
Change
+$5.46 (+2.59%)
Updated
May 2, 6:59 PM EST
5 days until earnings call
PDSB
Price
$3.73
Change
+$0.12 (+3.32%)
Updated
May 2, 6:59 PM EST
12 days until earnings call
Ad is loading...

Analysis and predictions MDGL vs PDSB

Header iconMDGL vs PDSB Comparison
Open Charts MDGL vs PDSBBanner chart's image
Madrigal Pharmaceuticals
Price$216.05
Change+$5.46 (+2.59%)
Volume$188.59K
CapitalizationN/A
PDS Biotechnology
Price$3.73
Change+$0.12 (+3.32%)
Volume$241.35K
CapitalizationN/A
View a ticker or compare two or three
MDGL vs PDSB Comparison Chart

Loading...

MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PDSBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
MDGL vs. PDSB commentary
May 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and PDSB is a Hold.

COMPARISON
Comparison
May 02, 2024
Stock price -- (MDGL: $210.08 vs. PDSB: $3.61)
Brand notoriety: MDGL and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 68% vs. PDSB: 65%
Market capitalization -- MDGL: $4.47B vs. PDSB: $132.41M
MDGL [@Biotechnology] is valued at $4.47B. PDSB’s [@Biotechnology] market capitalization is $132.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $578.54B to $0. The average market capitalization across the [@Biotechnology] industry is $2.62B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, PDSB is a better buy in the long-term than MDGL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 4 TA indicator(s) are bullish while PDSB’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 4 bullish, 5 bearish.
  • PDSB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than MDGL.

Price Growth

MDGL (@Biotechnology) experienced а +2.65% price change this week, while PDSB (@Biotechnology) price change was +11.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.13%. For the same industry, the average monthly price growth was -1.93%, and the average quarterly price growth was +1240.72%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 06, 2024.

PDSB is expected to report earnings on Aug 14, 2024.

Industries' Descriptions

@Biotechnology (+5.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
A.I.dvisor published
a Summary for PDSB with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($4.47B) has a higher market cap than PDSB($132M). MDGL YTD gains are higher at: -9.206 vs. PDSB (-27.364).
MDGLPDSBMDGL / PDSB
Capitalization4.47B132M3,387%
EBITDAN/AN/A-
Gain YTD-9.206-27.36434%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
MDGL vs PDSB: Fundamental Ratings
MDGL
PDSB
OUTLOOK RATING
1..100
695
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
57100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
6288
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (50) in the Pharmaceuticals Major industry is in the same range as MDGL (67) in the Pharmaceuticals Other industry. This means that PDSB’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (57) in the Pharmaceuticals Other industry is somewhat better than the same rating for PDSB (100) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew somewhat faster than PDSB’s over the last 12 months.

MDGL's SMR Rating (99) in the Pharmaceuticals Other industry is in the same range as PDSB (99) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to PDSB’s over the last 12 months.

MDGL's Price Growth Rating (62) in the Pharmaceuticals Other industry is in the same range as PDSB (88) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to PDSB’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLPDSB
RSI
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 4 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
PDSBDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSCRX22.240.04
+0.18%
Loomis Sayles Small Cap Value Retail
PMDDX17.430.01
+0.06%
Principal Small-MidCap Dividend Inc C
AGPIX9.63N/A
N/A
AGF Global Sustainable Equity I
AIVIX14.63-0.03
-0.20%
AB International Value I
JLVRX19.55-0.13
-0.66%
JPMorgan Large Cap Value R5

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with IBRX. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then IBRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+2.97%
IBRX - MDGL
62%
Loosely correlated
+6.51%
KA - MDGL
62%
Loosely correlated
-2.37%
VXRT - MDGL
61%
Loosely correlated
-2.06%
VBIV - MDGL
57%
Loosely correlated
-0.53%
ALXO - MDGL
56%
Loosely correlated
-0.41%
More

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with AXON. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
+7.76%
AXON - PDSB
43%
Loosely correlated
-0.75%
MDGL - PDSB
38%
Loosely correlated
+2.97%
INZY - PDSB
36%
Loosely correlated
+4.31%
MNKD - PDSB
35%
Loosely correlated
+5.60%
VCYT - PDSB
35%
Loosely correlated
+2.86%
More